[go: up one dir, main page]

MX2012000113A - Compuestos alcoxi-carbonil-amino-alquinil-adenosina y derivados de los mismos como agonistas a2ar. - Google Patents

Compuestos alcoxi-carbonil-amino-alquinil-adenosina y derivados de los mismos como agonistas a2ar.

Info

Publication number
MX2012000113A
MX2012000113A MX2012000113A MX2012000113A MX2012000113A MX 2012000113 A MX2012000113 A MX 2012000113A MX 2012000113 A MX2012000113 A MX 2012000113A MX 2012000113 A MX2012000113 A MX 2012000113A MX 2012000113 A MX2012000113 A MX 2012000113A
Authority
MX
Mexico
Prior art keywords
sub
alkynyl
carbonyl
alkoxy
derivatives
Prior art date
Application number
MX2012000113A
Other languages
English (en)
Inventor
Jayson M Rieger
Robert D Thompson
Anthony R Beauglehole
Frank W Schmidtmann
Original Assignee
Forest Lab Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forest Lab Holdings Ltd filed Critical Forest Lab Holdings Ltd
Publication of MX2012000113A publication Critical patent/MX2012000113A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de alcoxi-carbonil-amino-alquil-adenosina y derivados de los mismos y composiciones farmacéuticas que contienen los mismos, que son agonistas selectivos de receptores de adenosina A2A (ARs). Estos compuestos y composiciones son útiles como agentes farmacéuticos.
MX2012000113A 2009-06-30 2010-06-30 Compuestos alcoxi-carbonil-amino-alquinil-adenosina y derivados de los mismos como agonistas a2ar. MX2012000113A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22169209P 2009-06-30 2009-06-30
PCT/US2010/040651 WO2011002917A1 (en) 2009-06-30 2010-06-30 Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as a2a r agonists

Publications (1)

Publication Number Publication Date
MX2012000113A true MX2012000113A (es) 2012-02-29

Family

ID=42562595

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000113A MX2012000113A (es) 2009-06-30 2010-06-30 Compuestos alcoxi-carbonil-amino-alquinil-adenosina y derivados de los mismos como agonistas a2ar.

Country Status (13)

Country Link
US (1) US8263762B2 (es)
EP (1) EP2448953A1 (es)
JP (1) JP2012532140A (es)
KR (1) KR20120107065A (es)
CN (1) CN102666563A (es)
AU (1) AU2010266313A1 (es)
BR (1) BRPI1014224A2 (es)
CA (1) CA2766073A1 (es)
CL (1) CL2011003355A1 (es)
EA (1) EA201270102A1 (es)
IL (1) IL217190A0 (es)
MX (1) MX2012000113A (es)
WO (1) WO2011002917A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014022577A1 (en) 2012-08-01 2014-02-06 Lewis And Clark Pharmaceuticals, Inc. N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as a2a agonists
US9822141B2 (en) 2012-08-01 2017-11-21 Lewis And Clark Pharmaceuticals, Inc. N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
MXPA01007850A (es) 1999-02-01 2002-08-20 Univ Virginia Composiciones para tratar respuesta inflamatoria.
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US20010051612A1 (en) 2000-02-23 2001-12-13 Gloria Cristalli 2-Thioether A2A receptor agonists
US7262176B2 (en) 2001-08-08 2007-08-28 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
AU2002362443B2 (en) 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
AU2002357295A1 (en) 2001-12-18 2003-06-30 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
WO2003061670A1 (en) 2002-01-25 2003-07-31 Muscagen Limited Compounds useful as a3 adenosine receptor agonists
EP1537135B1 (en) * 2002-09-09 2009-11-25 Cv Therapeutics, Inc. Adenosine a3 receptor agonists
JP2006515276A (ja) 2002-10-22 2006-05-25 オスコテック株式会社 骨粗鬆症の予防及び治療効果を有するフラン誘導体並びにこれを含む薬学的組成物
AU2004209986C1 (en) 2003-02-03 2009-08-13 Gilead Palo Alto, Inc. Partial and full agonists of A1 adenosine receptors
WO2005097140A2 (en) * 2004-04-02 2005-10-20 Adenosine Therapeutics, Llc Selective antagonists of a2a adenosine receptors
JP2007535560A (ja) 2004-04-28 2007-12-06 シーブイ・セラピューティクス・インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
PL1758596T3 (pl) 2004-05-26 2011-01-31 Inotek Pharmaceuticals Corp Pochodne purynowe jako agoniści receptora adenozynowgo A1, oraz sposoby ich zastosowania
EP1778712B1 (en) 2004-08-02 2013-01-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0505219D0 (en) 2005-03-14 2005-04-20 Novartis Ag Organic compounds
WO2006101920A2 (en) 2005-03-18 2006-09-28 University Of Rochester Compositions and methods related to the manipulation of adenosine 2a receptor signaling for the treatment of hiv associated neuronal damage
US7589076B2 (en) 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
US7985754B2 (en) * 2006-07-17 2011-07-26 Trovis Pharmaceuticals, Llc Selective antagonists of A2A adenosine receptors

Also Published As

Publication number Publication date
US20110003766A1 (en) 2011-01-06
KR20120107065A (ko) 2012-09-28
WO2011002917A1 (en) 2011-01-06
AU2010266313A1 (en) 2012-01-19
EP2448953A1 (en) 2012-05-09
IL217190A0 (en) 2012-02-29
CL2011003355A1 (es) 2012-10-19
JP2012532140A (ja) 2012-12-13
BRPI1014224A2 (pt) 2019-09-24
CA2766073A1 (en) 2011-01-06
EA201270102A1 (ru) 2012-08-30
CN102666563A (zh) 2012-09-12
US8263762B2 (en) 2012-09-11

Similar Documents

Publication Publication Date Title
WO2008021849A3 (en) Novel compounds as antagonists or inverse agonists at opioid receptors
NZ703992A (en) N-alkyl 2-(disubstituted)alkynyladenosine-5’-uronamides as a2a agonists
MX2010001754A (es) Derivados de azepina como inhibidores de gamma secretasa.
SG173374A1 (en) Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
TW200800967A (en) Benzimidazole thiophene compounds
MX2009000884A (es) Derivados de piridizinona.
IL193894A0 (en) Pharmaceutical compositions containing luliconazole for external use
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
ATE483707T1 (de) 2-cyclopropylthiazolderivate
MX2008013520A (es) Agonistas del receptor de adenosina a3.
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
PA8792401A1 (es) Fenilendiaminas
TN2011000585A1 (en) Lxr modulators
IL189614A0 (en) Pharmaceutical compositions of telmisartan
ECSP088265A (es) Derivados de carboxamida como antagonistas del receptor muscarínico
EP2129672A4 (en) ESTER AND CARBAMATE AZAADAMANTANE DERIVATIVES AND METHODS OF USE
MX372721B (es) Ánalogos halogenados de agentes antifi-broticos.
WO2008011007A3 (en) Selective antagonists of a2a adenosine receptors
SG158091A1 (en) Imidazoazepinone compounds
MY146671A (en) Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents
WO2008116185A3 (en) Substituted pyrimidines as adenosine receptor antagonists
TW200740814A (en) Compounds
EA200900010A1 (ru) Замещенные 8-[6-амино-3-пиридил]ксантины
IL208325A0 (en) Stabilizing lipis compositions for oral pharmaceutical agents

Legal Events

Date Code Title Description
FA Abandonment or withdrawal